Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Recurrence 2Pancreatic Neoplasms 2Neoplasms 1Mesothelioma 1Lung Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gynecological Solid Tumors 1

Interventions

Bevacizumab 9pembrolizumab 5lenvatinib 5durvalumab 5atezolizumab 5tremelimumab 3fludarabine 3camrelizumab 3apatinib 3Ipilimumab 3Cyclophosphamide 3regorafenib 2Riluzole 2Radiotherapy 2Nivolumab 2Magnetic Resonance Imaging 2Idarubicin 2Blood Specimen Collection 2Biopsy 2yttrium chloride 1trastuzumab deruxtecan 1spartalizumab 1sintilimab 1pertuzumab 1ferric carboxymaltose 1epigallocatechin gallate 1donafenib 1cemiplimab 1brodalumab 1Yttrium-90 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Liver Neoplasms × Cell- and Tissue-Based Therapy × Clear all
NCT06196294 2024-06-26

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

Second Affiliated Hospital of Guangzhou Medical University

Phase 1 Recruiting
30 enrolled
GastrointestinalOther solid neoplasmThoracic

Liver Neoplasms, Lung Neoplasms, Mesothelioma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡